CALCIUM INJ DIN 00532762
Health Canada record
| Active ingredient(s) | CALCIUM GLYCEROPHOSPHATE 10 MG; CALCIUM LEVULINATE 15 MG |
|---|---|
| Dosage form | Liquid |
| Route | Intramuscular; Intravenous; Subcutaneous |
| Schedule | ETHICAL |
| Class | Human |
| ATC | A12AA20 CALCIUM (DIFFERENT SALTS IN COMBINATION) |
| Original market date | 31-Dec-1981 |
| Current status date | 18-Aug-2018 |
| Source | Health Canada DPD |
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CALCIUM GLYCEROPHOSPHATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 00052426 | CALPHOSAN SUSPENSION | AUSTIN, DIVISION OF VÉTOQUINOL N.-A. INC. | Suspension | CALCIUM GLYCEROPHOSPHATE 50 MG; CALCIUM LACTATE 50 MG | Cancelled Post Market |
| 00241571 | FORMULE 37805 | THERAPEUTIC FOODS CO. | Capsule | CALCIUM GLYCEROPHOSPHATE 22 MG; BETAINE HYDROCHLORIDE 27 MG; POTASSIUM BICARBONATE 18 MG; CHOLINE BITARTRATE 4 MG; RIBONUCLEIC ACID 3 MG | Cancelled Post Market |
| 00166219 | TRIOGENE FOR | PRODUITS FRANCAIS LABS INC. | Powder | CALCIUM GLYCEROPHOSPHATE 549.25 MG; GENTIANA LUTEA 53.3 MG; KOLA 161.2 MG; QUININE 71.37 MG; IRON 209.82 MG | Cancelled Post Market |
International API supply for CALCIUM GLYCEROPHOSPHATE
0 valid EDQM Certificates of Suitability from 0 holders.
Request a quote for CALCIUM INJ